Ellen J. Kim, MD

Selected Publications

• Willemze R, Assaf C, Bagot M, Beylot-Barry M, Berti E, Busschots AM, Cerroni L, Climent F, Diercks G, Geskin L, Gniadecki R, Gru AA, Guenova E, Guitart J, Jansen P, Kempf W, Kim E, Kim YH, Koldijk M, Marschalkó M, Mitteldorf C, Molgó M, Muniesa C, KJ Neelis, Olsen E, Ortiz-Romer PLo, Papadavid E, Pimpinelli N, Pulitzer M, Quaglino P, Querfeld C, Quint K, Scarisbrick JS, Schrader AMR, Stadler R, Vermeer M, Wehkamp U, Whittaker S, Wobser M. : European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. Br J Dermatol 193(6) : 1090-1100, Dec 2025
• Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM. : Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study. Journal of the American Academy of Dermatology 2025-05-01 J Am Acad Dermatol. 92(5) : 1100-1102, May 2025
• Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 92(3) : 634-636, Mar 2025
• Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome JAMA Dermatol 161(6) : 656-658, 2025
• Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol Nov 2024 Notes: doi: 10.1016/j.jaad.2024.10.095.
• Villasenor-Park J, Chung J, Kim EJ : Cutaneous B-cell Lymphomas/Cutaneous Oncology Hematology Oncology Clinics 38(5) : 1111, October 2024
• Silva GS, Kim EJ, Barta SK, Chung J : Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature Expert Rev Anticancer Ther 24(9) : 819-827, Sep 2024 Notes: doi: 10.1080/14737140.2024.2379914.
• Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. : Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma. International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C. April 2024
• Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E : Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies Transplant Cell Ther 24 Jan 2024 Notes: doi: 10.1016/j.jtct.2023.12.674. Epub ahead of print.
• Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK. : Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma Dermatologic Therapy Dec 2023 Notes: https://doi.org/10.1155/2023/7625926